remains one of the deadliest of all genitourinary cancers. The mainstay of treatment remains radical cystectomy. Recent success of adjuvant anti-PDL1 immunotherapy after surgery for lung cancer has infused interest in post-operative immunotherapy following radical cystectomy and several adjuvant trials are underway. However, surgery itself causes immune dysregulation, which could influence the response to adjuvant immune therapy. The influence of surgery on subsequent immunotherapy is unknown.
INTRODUCTION AND OBJECTIVES: Bladder cancer (BC)
remains one of the deadliest of all genitourinary cancers. The mainstay of treatment remains radical cystectomy. Recent success of adjuvant anti-PDL1 immunotherapy after surgery for lung cancer has infused interest in post-operative immunotherapy following radical cystectomy and several adjuvant trials are underway. However, surgery itself causes immune dysregulation, which could influence the response to adjuvant immune therapy. The influence of surgery on subsequent immunotherapy is unknown.
METHODS: C57BL/6 mice were challenged with BC and then subjected to anesthesia with or without surgery (2 cm laparotomy) under sterile conditions. Metastatic cancer was induced by injecting 0.5 x 10 6 MB49 bladder tumor cells via tail vein into male mice on the day of surgery. Orthotopic (bladder) cancer was induced by catheterizing the bladders of female mice and injecting poly-L-lysine followed by 0.08x10 6 MB49 cells, one day prior to surgery. Anti-PD-L1 was given intraperitoneally on days 1, 7, and 12 after surgery. Mice were followed for survival and necropsy was done at time of death. Immune studies were conducted on spleen and tumor-draining lymph nodes (TDLN) to examine the effect of surgery on T cell phenotypes.
RESULTS: Surgery caused a profound increase in pulmonary and liver metastasis associated with reduced survival in mice challenged with MB49 via tail vein (A). As potential mechanisms, surgery increased the percentage of exhausted splenic T cells characterized by expression of PD-1, TIM-3, and LAG-3 and diminished natural killer (NK) production of the pro-inflammatory cytokines IFN-g and TNF-a (B). Surgery alone had no effect on survival of mice that did not receive bladder tumors but did significantly decrease the efficacy of AE-PD-L1 immunotherapy against orthotopic MB49 bladder tumors (C). As expected, a-PD-L1 immunotherapy increased the generation of tumor-specific cells in TDLN, but surgery significantly reduced this effect (D).
CONCLUSIONS: Surgical stress dampens NK cell cytotoxic cytokines and promotes bladder cancer metastasis. Surgery also suppresses tumor-specific immunity and clinical response to anti-PD-L1 BC immunotherapy. These findings have important implications for surgical management of BC and the potential efficacy of adjuvant BC immunotherapy.
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MP57-07 LONG NON-CODING RNA SOX2OT PROMOTES STEMNESS CHARACTERISTICS AND DRUG-RESISTANCE OF BLADDER CANCER CELLS BY MODULATING SOX2
Yonghao Zhan*, Zhicong Chen, Shiming He, Xuesog Li, Liqun Zhou, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Cancer stem cells are considered responsible for many important aspects of tumors such as their self-renewal, tumor-initiating, metastasis and drug-resistance. SOX2 overlapping transcript (SOX2OT) is a novel long non-coding RNA that acts as a potential biomarker and involves in development of multiple cancers. Here, we elucidated the function and possible molecular mechanisms of the effect of SOX2OT on the biological behaviors of bladder cancer cells.
METHODS: The expression level of SOX2OT was determined by RT-qPCR in a total of 106 patients with urothelial bladder cancer and validated by online datasets. Bladder cancer stem cells (BCSCs) were isolated from bladder cancer cells using flow cytometry based on the stem cell markers CD44 and ALDH1. After the construction of SOX2OT knockdown cell lines, the malignant phenotypes (selfrenewal, metastasis, drug-resistance and tumourigenicity) of BCSCs were determined by using different assay. Downstream targets of SOX2OT were investigated by RNA-FISH, bioinformatics analysis, dual-luciferase reporter assay and western blot.
RESULTS: SOX2OT was highly expressed in bladder cancer and positively correlated with higher histological grade, advanced TNM stage and poor prognosis. Inhibition of SOX2OT repressed selfrenewal, metastasis and drug-resistance (Cisplatin) in vitro. Moreover, inhibition of SOX2OT also elicited delayed tumor growth of xenograft and a decrease in the number and size of lung metastases in vivo. Mechanistically, the bio-information analysis revealed that SOX2OT expression positively correlated with SOX2 expression and RNA-FISH results revealed that SOX2OT was mainly distributed in the cytoplasm of BCSC. Further experimental results demonstrated that SOX2OT functions as a miRNA sponge to positively regulate SOX2 expression by sponging the miR-200 cluster. Furthermore, overexpression of SOX2 reversed the malignant phenotype inhibition of BCSCs induced by silencing SOX2OT.
CONCLUSIONS: Taken together, SOX2OT is a promising novel prognosis biomarker in bladder cancer. That SOX2OT promotes stemness characteristics and drug-resistance of bladder cancer cells through regulating SOX2 may represent a target for clinical intervention.
